Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Open Label, Clinical Trial Evaluating Safety and Activity of Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Post-acute Sequelae of SARS-CoV2 Infection (PASC).

NCT05597800 is registered in ClinicalTrials.gov with Universita di Verona as lead sponsor.

NCT NCT05597800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05597800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Open Label, Clinical Trial Evaluating Safety and Activity of Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Post-acute Sequelae of SARS-CoV2 Infection (PASC).
Lead sponsor
Universita di Verona
Phase
Phase 2
Overall status
Not yet recruiting
Start date
February 1, 2023
Completion date
March 30, 2027
Enrollment
105 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hbv, hcv, hiv, long covid, nsclc stage iv